First Potential Lupus-Specific Treatment in Sight
BENLYSTA (TM) SUCCESSFUL IN FIRST OF TWO PIVOTAL CLINICAL TRIALS
WASHINGTON, July 20 /PRNewswire-USNewswire/ -- Today, Human Genome Sciences (HGS) and GlaxoSmithKline (GSK) announced positive results from a year-long clinical trial of BENLYSTA for treating lupus. Whe...
Innovative Psoriasis Treatment PSORENT(R) Announces Healthcare Cost Savings Potential Consistent with President Obama's Announcement on Healthcare Reform
PRINCETON, N.J., June 25 /PRNewswire/ -- "Congratulations President Obama on your agreement with large pharmaceutical companies to cut prescription costs for the elderly," says Mark D. Steele, president of NeoStrata Company, Inc. "We thought you should know that you have a little company in New Je...
CEL SCI Collaborators Demonstrate Novel L.E.A.P.S. Vaccines Immunize Mice Against Tuberculosis Antigens and Suggest Potential to Treat Swine and Other Influenzas
VIENNA, Va., June 5 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE AMEX: CVM ) announced today that its collaborators at the University of Hawaii reported on data at the annual American Society for Microbiology in Philadelphia, PA. This data demonstrates that vaccines utilizing its L.E.A...
Ethicon Endo-Surgery Studies Presented at DDW Demonstrate Potential of Pure NOTES Surgery With Company's Toolbox
CINCINNATI, June 3 /PRNewswire/ -- Ethicon Endo-Surgery, Inc. today announced that multiple studies presented at the 2009 Digestive Disease Week (DDW) demonstrate the company's novel, investigational* Toolbox enables natural orifice translumenal endoscopic surgery (NOTES) procedures without lap...
Scientists at The Karmanos Cancer Institute in Detroit Identify Potential New Target for Breast Cancer Therapy
Abstract # 25670
ORLANDO, Fla., May 29 /PRNewswire-USNewswire/ -- The American Society of Clinical Oncology (ASCO) has selected new breast cancer research conducted at the Barbara Ann Karmanos Cancer Institute in Detroit for posting on ASCO's Web site. Karmanos' potentially ground-breaking fi...
Cardium Announces Completion of Patient Recruitment in Phase 2b Clinical Trial of Excellarate(TM) for the Potential Treatment of Diabetic Foot Ulcers
SAN DIEGO, May 6 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM ) and its subsidiary Tissue Repair Company (TRC) today announced the completion of recruitment for the pioneering Phase 2b MATRIX clinical trial to evaluate the safety and efficacy of the Excellarate(TM) product cand...
Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
- Combination of R7227, protease inhibitor, and R7128, nucleoside polymerase inhibitor, shows significant potency in reducing viral load in patients with hepatitis C -
NUTLEY, N.J., BRISBANE, Calif., and PRINCETON, N.J., April 25 /PRNewswire-FirstCall/ -- Roche, InterMune, Inc. (Nasdaq: IT...
Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments
CHADDS FORD, Pa., Feb. 10 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP ) announced today that it has signed two research collaboration agreements to develop novel treatments for pain and to discover potential
treatments for cancer.
The first collaboration, with Harvar...
Study Shows Leconotide, an Investigative Calcium Channel Blocker, Has Potential as a Selective, Efficacious, Non-Opioid Pain Treatment
HONOLULU, Jan. 28 /PRNewswire/ -- Results of a pre-clinical study of
leconotide, an investigative calcium channel blocker, shows it has the
potential to be safe, selective, and efficacious as a new non-opioid treatment
for pain relief. It also holds promise in multiple drug delivery options
ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity
ZURICH, Switzerland, Jan. 9/PRNewswire/ -- ESBATech AG, a leading developer of antibody fragment therapeutics, today announced the initiation of the Phase I/IIa clinical development of its anti-TNF alpha antibody fragment ESBA105 in osteoarthritis (OA). This double-blind, randomized, placebo-contr...
RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
EAST HANOVER, N.J., Dec. 12 /PRNewswire/ -- New data from two early
clinical studies show that RAD001(R) (everolimus) may overcome resistance to
Herceptin(R) (trastuzumab)* in women with HER2-positive metastatic breast
cancer. These results support the initiation of a Phase III clinical trial
More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
- Tasigna front-line data demonstrating potential
in newly diagnosed patients with a life-threatening type of leukemia to be featured in two oral sessions at ASH
- Exjade results at ASH to show benefits for chronically transfused patients by significantly reducing toxic iron that can dama...
Study Shows Potential Benefits of Xolair(R) in Treating Children Suffering from Moderate or Severe Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids
- Results demonstrate clinically significant reduction in allergic
asthma attacks and further define Xolair safety profile in children age six
through 11 - this includes 11-year-old children, up to their 12th birthday
- Xolair is the only approved therapy to block IgE, which is associated
Landmark Study Demonstrates Potential of Radioimmunotherapy for Treatment of Indolent B-Cell Non-Hodgkin's Lymphoma
Zevalin(R) First-Line Indolent (FIT) Phase III Clinical Trial results published in Journal of Clinical Oncology
SEATTLE, Oct. 16 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
(CTI) (Nasdaq and MTA: CTIC) announced today that the Journal of Clinical
Oncology has published the...
Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease
-- Exploratory study shows clinical improvement in patients with pulmonary arterial hypertension (PAH)
-- Current treatment options have limited benefit for this debilitating, rapidly progressive and incurable blood vessel disease
-- Imatinib mesylate, available as Gleevec(R)...
RAD001 Granted Priority Review in the US Based on Potential to Fill Unmet Medical Need in Patients With Advanced Kidney Cancer
-- Regulatory applications to be submitted worldwide for RAD001 first submissions filed in the Hidden List US, EU and Switzerland
-- Data showing that RAD001 more than doubles time without tumor growth and reduced risk of disease progression by 70% now published in The...
Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum
The Study Demonstrates microRNAs Extracted From a Simple Blood Draw Have
to Serve as Effective Clinical Biomarkers for a Wide Range of Indications
Using This Proprietary Technology, Rosetta Genomics is Currently Developing a Blood-Based Te...
Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
EAST SETAUKET, N.Y., Aug. 12 /PRNewswire-FirstCall/ -- Lixte
Biotechnology Holdings, Inc. (OTC Bulletin Board: LIXT) announced today
that it had filed a patent application for the use of compounds the company
is developing for treatment of brain tumors as potential
Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
EAST SETAUKET, N.Y., Aug. 8 /PRNewswire-FirstCall/ -- Lixte
Biotechnology Holdings, Inc. (OTC Bulletin Board: LIXT) announced today
that lead compounds from each of two different types of drugs being
developed as potential
treatment for specific types of brain cancers have
activity against hum...
New AVAC Report on Pre-Exposure Prophylaxis Calls for Immediate Planning to Anticipate Study Results of Potential New HIV Prevention Option
Now is the time to anticipate and plan for various study outcomes
MEXICO CITY, Aug. 3 /PRNewswire/ -- The AIDS Vaccine Advocacy Coalition
(AVAC) today released a new report, Anticipating the Results of PrEP
Trials, calling for increased action from governments, global health
Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs
Study results pending publication in July print edition of Clinical Chemistry, available on Web
INDIANAPOLIS, July 23 /PRNewswire/ -- A Roche Diagnostics-sponsored
pilot study evaluating the use of N-terminal pro-B-type natriuretic peptide
(NT-proBNP) confirms the potent...
Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A
BRISBANE, Australia, July 22 /PRNewswire-FirstCall/ -- Following a
thorough review that concluded late yesterday, the Board of Progen
Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) today announced that it
had discontinued the PI-88 phase 3 study in liver cancer. Progen confirmed
Journal of Antimicrobial Chemotherapy Paper Supports Additional Role for Cethromycin as Potential Treatment for Infections Caused by Community- Associated Methicillin Resistant Staphylococcus Aureus (CA-MRSA)
CHICAGO, June 25 /PRNewswire-FirstCall/ -- Advanced Life Sciences
Holdings, Inc. (Nasdaq: ADLS ), a biopharmaceutical company engaged in the
discovery, development and commercialization of novel drugs in the
therapeutic areas of infection, cancer and respiratory diseases, today
New Global Survey Exposes Considerable Burden of Fibromyalgia Including Potential Economic Impact
PARIS, June 13 /PRNewswire/ --
- Lack of Physician Education May Contribute to Problem
A new global survey of fibromyalgia patients and physicians shows that
fibromyalgia, a chronic widespread pain condition, results in poor quality
of life and poses a financial burden on patients often re...
Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients
- Phase II Data Indicate Overall and Disease-Free Survival -
WAYNE, N.J., June 5 /PRNewswire/ -- Results from an adjuvant trial in
high-risk melanoma patients demonstrated that a majority of patients
treated with Leukine(R) (sargramostim) achieved disease-free and/or overall
Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
- Randomized Phase II data show RAD001 significantly increased efficacy of
letrozole tablets in women with newly diagnosed hormone-positive breast cancer
- Phase I studies suggest RAD001 may help overcome a major pathway of resistance to ...
New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens
TYKERB Demonstrates Activity in Combination with Other Targeted Therapies and as Monotherapy Across A Range of Breast Cancer Settings
- First Phase II data investigating the dual inhibition of HER2 and VEGF
pathways with two oral, small molecule tyrosine-kinase inhibitors (TYKERB
Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer
-Study Results Show 100-Fold More Radiation Delivered to Tumor as Compared to Other Organs-
-All Patients Surpassed Expected Median Survival Time at Lowest Planned Dose Level-
CHICAGO and TUSTIN, Calif., May 31 /PRNewswire-FirstCall/ -- ...
Observational Studies Assess the Potential Impact of Limiting Erythropoiesis-Stimulating Agent Availability on Frequency of Blood Transfusions
CHICAGO, May 30 /PRNewswire/ -- Data from three observational studies
reported at the American Society of Clinical Oncology (ASCO) Annual Meeting
evaluated transfusion-related outcomes in cancer chemotherapy patients with
various hemoglobin (Hb) levels prior to or during administration of
New Data on MAGE-A3 Cancer Immunotherapy Support Potential Novel Options of Treating Non-Small Cell Lung Cancer and Melanoma
Gene Expression Profiling of Tumor is Correlated With Clinical Response
CHICAGO, May 30 /PRNewswire-FirstCall/ -- New data presented by
GlaxoSmithKline (GSK) today highlighted the potential
investigational MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI)
through results of three...
Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
-- Phase 1 RDEA119 data expected in second half of 2008 --
-- Presentation at the Seventh Annual JMP Securities Research Conference on
May 21st canceled; webcast of corporate update scheduled during Ardea's Annual Stockholder Meeting on May 22nd at 9:30 a.m. PT --
SAN DIEGO, May...
Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib)
FRIMLEY, England, May 20 /PRNewswire-FirstCall/ --
- Tasigna(R) (nilotinib) Effective in 77% of Patients Resistant or
Intolerant to Prior Treatment in the Chronic (Early) Phase of Chronic
Myeloid Leukaemia (CML)(1)
- Highly Targeted Nature of Tasigna(R) Tackles the Root Cause of CML
Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
- Unprecedented amount of research reflects depth and breadth of
collaboration with investigators worldwide to develop new treatments for diverse forms of cancer - Plenary session to highlight impact of Zometa(R), the leading IV
bisphosphonate, on relapse rate of ...
Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD)
GREEN BAY, Wis., May 15 /PRNewswire/ -- Omega 3 fatty acids bound to
phospholipids deserves to be further considered as a credible natural
alternative and may have beneficial effect on impulsivity in ADHD patients,
recent in vivo French study reveals. While several studies have reported
Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization
DOYLESTOWN, Pa., May 14 /PRNewswire-FirstCall/ -- The Quigley
Corporation (Nasdaq: QGLY ) announced positive results from a study
conducted by its wholly owned subsidiary, Quigley Pharma Inc., which was
conducted in chickens to evaluate the anti-viral activity of its compound
QR448(a). The co...
Data Presented at AAN Support Potential for Adjunctive use of Intravenous Lacosamide as Short-Term Replacement for Oral Treatment in Partial Epilepsy
SMYRNA, Ga., April 18 /PRNewswire/ -- Data presented today at a
platform session of the 60th Annual Meeting of the American Academy of
Neurology (AAN) in Chicago support the potential
for adjunctive use of
intravenous lacosamide 200-600 mg/day using infusion durations as fast as
10 minutes for...
Pharmacyclics' Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
SAN DIEGO and SUNNYVALE, Calif., April 16 /PRNewswire-FirstCall/ --
Pharmacyclics, Inc. (Nasdaq: PCYC ) today presented preclinical results
demonstrating the anti-tumor activity of PCI-27483, the company's
small-molecule Factor VIIa inhibitor. The data were presented during the
Mayo Clinic Study Identifies Potential Causes of Young-Onset Dementia
ROCHESTER, Minn., April 15, 2008 /PRNewswire-USNewswire/ -- A new Mayo
Clinic study found that young-onset dementia often is caused by
neurodegenerative or autoimmune/inflammatory conditions, but only rarely by
Alzheimer's disease. This differs substantially from the common causes of
Roche Gains Access to Important Oncology Target With Potential for Treating Major Cancers Such as Breast and Lung; First Drug Candidate in Phase I Clinical Testing
- Second research program centered on potential
target in inflammatory indications such as rheumatoid arthritis -
NUTLEY, N.J., April 15 /PRNewswire/ -- Roche announced today that it
will acquire Piramed Limited, a privately-owned UK company focusing on
therapeutics targeting PI...
Michael J. Fox Foundation Announces $5.6-Million Award for Phase 2 Clinical Trial Studying Neuroprotective Potential of Inosine
NEW YORK, April 14 /PRNewswire-USNewswire/ -- The Michael J. Fox
Foundation announced a $5.6-million award to drive a Phase 2 clinical trial
to investigate the potential
of inosine -- a naturally occurring chemical
that gives rise to urate in the body -- to slow or stop the progression of